Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rohit Loomba

Showing results (51-60 of 748) with videos related to

Pageof 75
Sort By:
Alimentary Pharmacology & Therapeutics|March 1, 2025
Editorial: Balancing the Yin and Yang of Alcohol-Associated Liver Disease-Integrating Pathophysiology, Liver-Directed Therapy, and Addiction Management. Authors' ReplyLuis Antonio Díaz, Rohit Loomba
Alimentary Pharmacology & Therapeutics|November 4, 2025
Letter: Safety and Tolerability of Injectable Extended-Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol-Associated Liver Disease-Authors' ReplyLuis Antonio Díaz, Rohit Loomba
Nature Reviews. Gastroenterology & Hepatology|September 18, 2013
The global NAFLD epidemicRohit Loomba, Arun J Sanyal
The Lancet. Gastroenterology & Hepatology|July 15, 2023
Semaglutide in NASH-related cirrhosis: still a long way to go? - Authors' replyRohit Loomba, Philip N Newsome
Antiviral Therapy|February 21, 2008
Treatment of chronic hepatitis BRohit Loomba, T Jake Liang
Hepatology (Baltimore, Md.)|September 15, 2019
The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis Caused by NASHRohit Loomba, Leon A Adams
Hepatology (Baltimore, Md.)|February 20, 2019
The Intestinal Microbiome, Plasma Metabolome, and Liver Transcriptome: A Conspiracy Driving Hepatic SteatosisWajahat Z Mehal, Rohit Loomba
Nature Metabolism|February 22, 2024
From NAFLD to MASLD: implications of the new nomenclature for preclinical and clinical researchCynthia L Hsu, Rohit Loomba
Seminars in Liver Disease|July 9, 2024
Noninvasive Tests to Assess Fibrosis and Disease Severity in Metabolic Dysfunction-Associated Steatotic Liver DiseaseMonica A Tincopa, Rohit Loomba
Clinical Liver Disease|December 16, 2022
Magnetic resonance imaging proton density fat fraction as an imaging-based biomarker of treatment response in patients with nonalcoholic steatohepatitisJonathan G Stine, Rohit Loomba
Pageof 75

Showing results (51-60 of 748) with videos related to

Sort By:
Pageof 75
Alimentary Pharmacology & Therapeutics|March 1, 2025
Editorial: Balancing the Yin and Yang of Alcohol-Associated Liver Disease-Integrating Pathophysiology, Liver-Directed Therapy, and Addiction Management. Authors' ReplyLuis Antonio Díaz, Rohit Loomba
Alimentary Pharmacology & Therapeutics|November 4, 2025
Letter: Safety and Tolerability of Injectable Extended-Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol-Associated Liver Disease-Authors' ReplyLuis Antonio Díaz, Rohit Loomba
Nature Reviews. Gastroenterology & Hepatology|September 18, 2013
The global NAFLD epidemicRohit Loomba, Arun J Sanyal
The Lancet. Gastroenterology & Hepatology|July 15, 2023
Semaglutide in NASH-related cirrhosis: still a long way to go? - Authors' replyRohit Loomba, Philip N Newsome
Antiviral Therapy|February 21, 2008
Treatment of chronic hepatitis BRohit Loomba, T Jake Liang
Hepatology (Baltimore, Md.)|September 15, 2019
The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis Caused by NASHRohit Loomba, Leon A Adams
Hepatology (Baltimore, Md.)|February 20, 2019
The Intestinal Microbiome, Plasma Metabolome, and Liver Transcriptome: A Conspiracy Driving Hepatic SteatosisWajahat Z Mehal, Rohit Loomba
Nature Metabolism|February 22, 2024
From NAFLD to MASLD: implications of the new nomenclature for preclinical and clinical researchCynthia L Hsu, Rohit Loomba
Seminars in Liver Disease|July 9, 2024
Noninvasive Tests to Assess Fibrosis and Disease Severity in Metabolic Dysfunction-Associated Steatotic Liver DiseaseMonica A Tincopa, Rohit Loomba
Clinical Liver Disease|December 16, 2022
Magnetic resonance imaging proton density fat fraction as an imaging-based biomarker of treatment response in patients with nonalcoholic steatohepatitisJonathan G Stine, Rohit Loomba
Pageof 75